ActoGeniX preclinical data

In a mouse model of Type I diabetes, ActoGeniX's oral ActoBiotic for Type I diabetes plus low-dose systemic anti-CD3 mAbs stably reverted overt autoimmune diabetes in a significantly greater proportio...